Rapid FDA Review For Roche’s SMA Contender
Physicians Keen On Oral Formulation
Executive SummaryRoche files quickly to keep up with Novartis’s gene therapy Zolgensma.
You may also be interested in...
Keeping Track Of Thanksgiving Leftovers: Risdiplam, Artesunate Highlight Glut Of Submissions/Filings
Yes, we know they should be out of the fridge by now, but here are the highlights of submissions and filings during the Thanksgiving week.
The roller coaster ride for Novartis with its high-profile gene therapy Zolgensma continues as the FDA places a partial hold on trials of an intrathecal version aimed at older SMA patients on the back of nerve inflammation seen in a preclinical study.
Janssen’s hemato-oncology success rolls on with impressive new overall survival data